BALTIMORE (Stockpickr) -- The S&P 500 is knocking out new highs this week, but that's not stopping some of Wall Street's biggest names from looking "toxic" as we head into March. Own these names at your own peril.
Over the course of this broad market rally, there's been a bigger-than-normal gap between the leaders and the laggards. In a very real way, the S&P 500's 22% run higher in the last 12 months has magnified the benefits of owning momentum leaders -- as well as the underperformance you'll see if you hang onto the toxic names.
Want to secure market-beating performance in 2014? Then avoiding the performance drags on your portfolio is more than half the battle. That's why we're taking a technical look today at five toxic stocks you should start selling.
>>5 Big Charts to Trade for Gains
Just to be clear, the companies I'm talking about today aren't exactly junk. By that, I mean they're not next up in line at bankruptcy court. But that's frankly irrelevant; from a technical analysis standpoint, sellers are shoving around these toxic stocks right now. For that reason, fundamental investors need to decide how long they're willing to take the pain if they want to hold onto these firms in the weeks and months ahead. And for investors looking to buy one of these positions, it makes sense to wait for more favorable technical conditions (and a lower share price) before piling in.
Top 10 Prefered Companies To Buy Right Now: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By Brian Orelli]
It's certainly harder than it sounds, but can be very profitable if you can find the next Celgene (NASDAQ: CELG ) . A 14-bagger over 10 years? Most investors would gladly take that kind of return even if it's only a small portion of their portfolio.
- [By Ben Levisohn]
Biotech stocks have been slammed recently and Morgan Stanley believes it’s time to start differentiating between the fundamentals of companies like Amgen (AMGN), Biogen Idec (BIIB), Celgene (CELG) and Gilead Sciences (GILD).
- [By Ben Levisohn]
Investors don’t appear to agree. Shares of Gilead Sciences have dropped 0.4% to $88.56 at 3:01 p.m. on a day when other biotech stocks are rising. Celgene (CELG) has gained 1.5% to $89.13, Regeneron (REGN) has advanced 1.1% to $317.96 and Biogen Idec (BIIB) has risen 1.1% to $322.62. The iShares Nasdaq Biotechnology ETF (IBB) is up 0.6% at $257.10.
- [By Maxx Chatsko]
Early this morning, Celgene (NASDAQ: CELG ) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide) in B-Cell chronic lymphomatic leukemia. The trial enrolled 450 elderly patients who had not undergone prior treatments and compared Revlimid against Leukeran (chlorambucil) from GlaxoSmithKline (NYSE: GSK ) . Unfortunately, a higher number of patient deaths were observed in the Revlimid arm, which forced the Food and Drug Administration to place the trial on clinical hold last week and the eventual discontinuation today. What does it mean for patients? Is this a blow to investors? Let's review.
Top 10 Tech Companies For 2014: Cyan Inc (CYNI)
Cyan, Inc., incorporated on October 25, 2006, has carrier-grade networking solutions that transform legacy networks into open, high-performance networks. The Company�� solutions include high-capacity, multi-layer switching and transport platforms, as well as a carrier-grade software-defined networking platform and applications. The Company�� solutions enable network operators to virtualize their networks, accelerate service delivery. The Company has designed its solutions to provide a range of applications, including business Ethernet, Wireless and broadband support services and cloud connectivity. The Company also offer high-capacity, multi-layer switching and transport platforms, known as its Cyan Z-Series, that have been designed to support the multiple concurrent technologies used in regional and metro networks, including both Ethernet-based services, as well as optical services.
The Company�� Z-Series platforms have been designed to transport traffic over network layer, utilizing both electrical and optical domains, to enable network operators to maximize network capacity at the lowest cost per bit. The Company�� customers range from service providers to high-performance data center and large, private network operators.
Advisors' Opinion:- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are Cyan Inc.(CYNI), Neurocrine Biosciences Inc.(NBIX) and SandRidge Energy Inc.(SD)
Top 10 Tech Companies For 2014: Timios National Corp (HOMS)
Timios National Corporation, formerly Homeland Security Capital Corporation, incorporated on August 12, 1997, provides radiological, nuclear, environmental, disaster relief and electronic security solutions to government and commercial customers. The Company is engaged in the strategic acquisition, operation, development and consolidation of companies operating in the chemical, biological, radiological, nuclear and explosive, (CBRNE), incident response and security marketplaces within the homeland security industry. It is building consolidated enterprises (platform companies) through the acquisition and integration of businesses in the homeland security industry, particularly businesses focused on CBRNE incident response. In August 2011, the Company sold its Nexus Technologies Group. In October 2011, the Company sold its Safety and Ecology Holding Corporation subsidiary to Perma-Fix Environmental Services, Inc. In May 2012, the Company announced the acquisition by its subsidiary Timios, Inc. of Glenn County Title Company. In June 2013, Timios National Corp announced that it has completed the purchase of Glenn County Title Company (GCTC). In September 2013, Timios National Corp announced that it had executed a purchase agreement for the assets of Adobe Title, LLC.
The Company offers a range of management and operational services to each of its subsidiaries through a team of dedicated professionals. Its subsidiaries compensate its holding company for such services. Its core services include environmental remediation and restoration, regulatory compliance, facilities management, facility deactivation, decommissioning and demolition, emergency response, design and construction services and security integration to the United States government agencies, such as the Department of Energy (DOE), the Department of Defense (DoD), the Environmental Protection Agency (EPA), the Federal Emergency Management Agency (FEMA), the United states Army Corps of Engineers and the National Aeronautics and Space ! Administration (NASA). It conducts its operations through Safety & Ecology Holdings Corporation (Safety), its wholly owned subsidiary; Nexus Technologies Group, Inc. (Nexus), its 93% owned subsidiary, and Polimatrix, Inc. (PMX), its joint venture. Safety is an international provider of environmental, nuclear and radiological infrastructure remediation, disaster relief solutions and advanced construction services. Nexus designs, develops and installs integrated security systems for government and commercial clients. PMX markets, sells and distributes radiological detection equipment.
Safety & Ecology Holdings Corporation
Safety is a provider of global environmental, hazardous and radiological infrastructure remediation, upgrades and nuclear services in the United States and the United Kingdom. Safety�� main business areas and service offerings include decommissioning and remediation environmental and remedial consultancy services; environmental and consultancy services; nuclear energy design, build, refurbishment and operational support services, and instrumentation and measurement technologies. Safety offers a range of services that include characterization, decontamination, decommissioning of facilities, soil and groundwater remediation, infrastructure reduction and demolition, site preparation, excavation, and remedial system construction; underground and overhead utility installation; electrical and mechanical installation; security fencing and device installation and upgrades; building renovation; piping; roadways, parking lots, and drainage system construction/repair, and landfill remediation and capping.
Safety engages in facility deactivation, demolition and closure solutions, including project investigation; radiological pre-engineering; demolition planning; removing above ground structures and structural components; storing, testing, certifying, processing and shipping nuclear waste, and abatement of hazardous materials. Safety focuses its service offe! ring on t! he application and integration of health physics, industrial hygiene, hazardous material consultancy and safety and health. In addition, Safety couples its technology with its instrumentation offering, on-site radiological laboratory capabilities and mobile radiological materials license to provide radiological services and consultation. Safety provides integrated services to the nuclear energy industry. Safety provides specialized services to a customer base, including government agencies, commercial customers and major engineering and construction companies around the world that are focused in the nuclear new plant deployment initiative, facility operation, decommissioning and refurbishment. The elements of Safety�� technology offering are instrumentation services and instrumentation technology, both of which are targeted to field investigations, characterizations of contaminants and clean-up and material management and disposal solutions.
The Company competes with Stoller, Cabrera, Portage, LATA Northwind, Demco, Eagle, Pro2Serv, PMTech, Navarro, Energy Solutions, the Washington Group, Tetra Tech, Shaw Environmental and C2HM Hill.
Nexus Technologies Group, Inc.
Nexus is a mid-Atlantic security integrator for the corporate and governmental security markets that specializes in the engineering and installation of custom designed integrated electronic security solutions, including access control, alarm, closed circuit television (CCTV), video, communication, perimeter protection and bomb and metal detection security systems. Nexus provides solutions to protect people, property and assets. As a systems integrator, Nexus designs, customizes, installs, integrates and maintains closed CCTV, access control, video and communication systems for its customers. Nexus has undertaken projects in a range of markets, including financial services, corporate and commercial, healthcare, government, nuclear utility services, public transportation, airports, industrial complexes,! museums,! prisons, higher education and data centers. As a provider of custom engineered integrated security solutions, including access control, alarm/intrusion, CCTV, communication, perimeter protection and bomb and metal detection security systems, Nexus is aligned with original equipment manufacturers (OEMs). Nexus has focused on five sectors in which it intends to expand, both vertically and horizontally. These sectors are Financial Institutions, Infrastructure Security, Government Facilities, Education Facilities and Corporate Markets.
Financial Institutions include banks, brokerage facilities, trading facilities and foreign currency exchange centers. Infrastructure Security include nuclear power generating facilities, water processing facilities, electricity generating facilities, power transfer stations and transportation centers, which include highway, bridge, tunnel, airport, rail and port security. Government Facilities include federal, state and local government buildings and offices, domestic and foreign embassies, military installations and police and fire department operations centers. Education Facilities include grammar, high school and college buildings, dorms and campuses, satellite learning centers and daycare centers. Corporate Markets include office buildings and grounds, parking lots, garages, retail locations, warehouses and apartment and condominium complexes.
The Company competes with Henry Brothers Electronics, Inc., Diebold, Inc. and ADT.
POLIMATRIX, INC.
PMX is a total solutions provider delivering radiation and nuclear protection and detection services through several engineered portable and stationary devices. PMX�� business plan is the development and marketing of radiological detection products and services. PMX has developed a range of domestic and international marketing initiative in Washington, DC, Virginia and Illinois. These states have used the PMX detection devices for a range of detection, prevention and first respon! der activ! ities. PMX�� product line of portable detection devices are designed to detect potential threats and can be positioned along transportation routes or carried by nuclear power generating facility security personnel. It operates PMX with the assistance of Safety�� personal.
The Company competes with Thermo Scientific and Canberra.
Advisors' Opinion:- [By Peter Graham]
However, there have been no further updates since then. A quick look on both Google Finance and Yahoo! Finance reveals the latest financials date from the end of September 2012 ��meaning its investor beware.
Timios National Corp (OTCMKTS: HOMS) Has No News Beyond FilingsSmall cap Timios National Corp is involved in the strategic acquisition, development and consolidation of real estate service businesses. Former Maryland Congressman C. Thomas McMillen, who served three consecutive terms in the U.S. House of Representatives from the 4th Congressional District of Maryland, heads the company. On Friday, Timios National Corp sank 32.28% to $1.28 for a market cap of $3.01 million plus HOMS is up 54.2% over the past year and up 1,013% over the past five years according to Google Finance.
- [By Peter Graham]
Small cap stocks Timios National Corp (OTCMKTS: HOMS) and Lattice Inc (OTCMKTS: LTTC) surged 54.29% and 20.83%, respectively, while Unique Pizza & Subs Corp (OTCMKTS: UPZS) sank 27.27% last Friday. But today is a new trading week with the last two trading days for the year. So what will these three small caps do today, tomorrow and after New Years�� Here is a closer look:
Top 10 Tech Companies For 2014: Glu Mobile Inc.(GLUU)
Glu Mobile Inc. designs, markets, and sells mobile games worldwide. It develops original games based on its intellectual property comprising Big Time Gangsta?, Blood & Glory, Bug Village, Contract Killer, Contract Killer: Zombies, Eternity Warriors, Frontline Commando, Gun Bros, Men vs. Machines, Stardom: The A-List, Super K.O. Boxing and Toyshop Adventures. The company also develops games based on licensed intellectual property consisting of Build-a-lot, Call of Duty, Deer Hunter, DJ Hero, Guitar Hero, Family Feud, Family Guy, Lord of the Rings, Paperboy, The Price Is Right, Transformers, Who Wants to Be a Millionaire?, and World Series of Poker. It offers a portfolio of action/adventure and casual games to smartphones and tablet devices users through direct-to-consumer digital storefronts, as well as to feature phone users served by wireless carriers and other distributors. The company was formerly known as Sorrent, Inc. and changed its name to Glu Mobile Inc. in May 20 05. Glu Mobile Inc. was incorporated in 2001 and is headquartered in San Francisco, California.
Advisors' Opinion:- [By Paul Ausick]
Glu Mobile Inc. (NASDAQ: GLUU) held its IPO in May of 2007 and raised $84 million on the sale of 7.3 million shares at a price of $11.50. Like Zynga, shares peaked around $14 within a few months, and the stock trades today at around $5 a share, up from near $2 a share last September. The shares have gained about 33% in the past three weeks, mostly due to the company’s freemium business model, where the games are free to play and in-app transactions of $1.99 or less keep players opening their wallets.
Top 10 Tech Companies For 2014: Leap Wireless International Inc.(LEAP)
Leap Wireless International, Inc., together with its subsidiaries, provides digital wireless services under the ?Cricket? brand name in the United States. The company offers unlimited local and the U.S. long distance services from various Cricket service area and unlimited text messaging services, as well as mobile Web, 411 services, navigation, and data back-up. It also provides BridgePay, a flexible payment option for customers to use and pay for the company?s cricket wireless service; handsets and devices with various features; cricket broadband service, an unlimited mobile broadband service that allows customers to access the Internet through their computers; Cricket PAYGo Service, a pay-as-you-go unlimited prepaid wireless service designed for customers who prefer the flexibility and control offered by traditional prepaid services; and Muve Music Service, an unlimited music download service for mobile handsets in select cricket markets. In addition, the company off ers voice and data roaming services. It markets its cricket handsets and services, primarily through company-owned retail stores and kiosks, as well as through authorized dealers and distributors, including premier dealers, local market authorized dealers, national mass-market retailers, and other indirect distributors. As of December 31, 2010, the company offered services in 35 states and the District of Columbia to approximately 5.5 million customers. Leap Wireless International, Inc. was founded in 1998 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Mani]
The best way to play the increasing value of the Lower 700 Block A Spectrum is through the purchase of Leap Wireless International, Inc. (NASDAQ:LEAP) stock now in order to own the remaining stub after the rest of the LEAP's assets are acquired by AT&T, Inc. (NYSE:T) for $15 a share.
- [By Evan Niu, CFA]
Leap Wireless' (NASDAQ: LEAP ) Cricket brand offers a $150 rebate, bringing the entry-level iPhone 5 down to $500. Cricket is also a prepaid carrier with no contracts, and Leap absolutely pays subsidies. On the most recent conference all, CFO R. Perley McBride noted that the company has made progress reducing subsidy costs, which were down $24 million sequentially in the fourth quarter. Leap still needs to ramp up iPhone selling efforts, since it's nowhere near on target for its iPhone purchase commitments.
Top 10 Tech Companies For 2014: Nanometrics Incorporated(NANO)
Nanometrics Incorporated provides high-performance process control metrology systems used primarily in the fabrication of integrated circuits, high-brightness LEDs, data storage devices, and solar photovoltaics. It offers automated metrology systems that provide optical critical dimension, thin film metrology, and wafer stress for transistor and interconnect metrology applications; the Lynx cluster metrology platform for use in wafer metrology applications, including optical critical dimension, overlay, and thin film process control; and integrated metrology systems, which provide near real-time measurements. The company's automated and integrated systems are also used in various process control applications, including dimension and film thickness measurement, device topography, and defect inspection, as well as used in the analysis of other film properties, such as optical, electrical, and material characteristics. Its process control solutions are deployed in the fabrica tion process from front-end-of-line substrate manufacturing to high-volume production of semiconductors and other devices, and to wafer-scale packaging applications. The company sells its metrology and inspection systems directly and through original equipment manufacturer channels to semiconductor manufacturers and equipment suppliers, and producers of high-brightness-LEDs, solar photovoltaics, data storage devices, silicon wafers, and photomasks worldwide. Nanometrics Incorporated was founded in 1975 and is headquartered in Milpitas, California.
Advisors' Opinion:- [By Steve Symington]
What:�Shares of Nanometrics Incorporated� (NASDAQ: NANO ) �popped more than 10% during Wednesday's intraday trading, then settled to close up 7% after the company turned in better-than-expected fourth quarter earnings.�
Top 10 Tech Companies For 2014: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi.
No comments:
Post a Comment